This site is intended for U.S. Healthcare Professionals.

ONUREG® is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Request a Rep

ONUREG® can help your patients live longer1

In QUAZAR® AML-001, the pivotal, randomized, double-blind, phase III study, ONUREG demonstrated a statistically significant improvement vs placebo in median OS: 24.7 months (95% CI: 18.7, 30.5) vs 14.8 months (95% CI: 11.7, 17.6) , respectively (HR: 0.69 [95% CI: 0.55, 0.86; P=0.0009]).1 Review Overall Survival Data